Form D — X4 Pharmaceuticals, Inc
0001470831-25-000145 · filed Aug 25, 2025
Figures are issuer-reported and describe stored filings. Data coverage and methodology.
Check this disclosure on SEC EDGAR · More Biotechnology filings
Offering
- Industry
- Biotechnology
- Exemptions
- Rule 506(b)
- Reported offering amount
- $84,999,985
- Reported amount sold
- $84,999,985
- Minimum investment
- $0
- Investors
- —
- Sales commission
- —
- Finders' fees
- —
Issuer
- Name
- X4 Pharmaceuticals, Inc
- CIK
- 1501697
- Entity
- Corporation
- Jurisdiction
- DELAWARE
- Year incorporated
- —
- Address
- 61 NORTH BEACON STREET
BOSTON, Massachusetts 02134 - Phone
- 857-529-8300
Related persons
May not be accurate — issuers self-report this list and the SEC does not verify it. Cross-check the original SEC EDGAR filing if accuracy matters.
-
Mark Baldry · Executive OfficerBOSTON, Massachusetts Find on LinkedIn ↗
-
Adam Craig · Executive OfficerBOSTON, Massachusetts Find on LinkedIn ↗
-
John Volpone · Executive OfficerBOSTON, Massachusetts Find on LinkedIn ↗
-
Christophe Arbet-Engels · Executive OfficerBOSTON, Massachusetts Find on LinkedIn ↗
-
Mary DiBiase · Executive OfficerBOSTON, Massachusetts Find on LinkedIn ↗
-
David Kirske · Executive OfficerBOSTON, Massachusetts Find on LinkedIn ↗
-
Gary J. Bridger · DirectorBOSTON, Massachusetts Find on LinkedIn ↗
-
Francoise De Craecker · DirectorBOSTON, Massachusetts Find on LinkedIn ↗
-
Murray W. Stewart · DirectorBOSTON, Massachusetts Find on LinkedIn ↗
-
Michael S. Wyzga · DirectorBOSTON, Massachusetts Find on LinkedIn ↗
View the original filing on SEC EDGAR ↗